Management of osteoarticular fungal infections in the setting of immunodeficiency.

Clicks: 318
ID: 101886
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 4 articles by views in expert review of anti-infective therapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
: Osteoarticular fungal infections (OAFIs) complicate the clinical course of high-risk patients, including immunosuppressed individuals. Their management, however, despite being intricate, is governed by evidence arising from sub-optimal quality research, such as case series. Guidelines are scarce and when present result in recommendations based on low quality evidence. Furthermore, the differences between the management of immunocompromised and immunocompetent patients are not distinct. This is a narrative review after a literature search in PubMed, up to November 2019.: The major fungal groups causing osteomyelitis and/or arthritis are spp., spp., non- filamentous fungi, non- yeasts and endemic dimorphic fungi. Their epidemiology is briefly analyzed with emphasis on immunodeficiency and other risk factors. Management of OAFIs includes appropriate antifungal drug therapy (liposomal amphotericin B, triazoles or echinocandins), local surgery and immunotherapy for primary immunodeficiencies. Cessation of immunosuppressive drugs is also mandated.: Management of OAFIs includes affordable and available options and approaches. However, research on therapeutic practices is urgently required to be further improved, due to the rarity of affected patients. Evolution is expected to translate into novel antifungal drugs, less invasive and precise surgical approaches and targeted enhancement of immunoregulatory pathways in defense of challenging fungal pathogens.
Reference Key
papachristou2020managementexpert Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Papachristou, Savvas G;Iosifidis, Elias;Sipsas, Nikolaos V;Gamaletsou, Maria N;Walsh, Thomas J;Roilides, Emmanuel;
Journal expert review of anti-infective therapy
Year 2020
DOI
10.1080/14787210.2020.1748499
URL
Keywords
surgery treatment fungi arthritis osteomyelitis antifungals immunodeficiency osteoarticular

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.